Diabetology International最新文献

{"title":"Unraveling the pathophysiology of type 2 diabetes with a new selectively bred animal model, the Oikawa-Nagao mouse.","authors":"Mototsugu Nagao","doi":"10.1007/s13340-024-00784-9","DOIUrl":"10.1007/s13340-024-00784-9","url":null,"abstract":"<p><p>Type 2 diabetes (T2D) is a polygenic disease, and the development of animal models by selective breeding is crucial for understanding its etiology, pathophysiology, complications, and treatments. We recently developed a new T2D model, the Oikawa-Nagao (ON) mouse, by selectively breeding mice with inferior glucose tolerance [diabetes-prone (ON mouse DP®; ON-DP) strain] and superior glucose tolerance [diabetes-resistant (ON mouse DR®; ON-DR) strain] on a high-fat diet. ON-DP mice are predisposed to develop diabetes and obesity after being fed a high-fat diet, compared to ON-DR mice. These phenotypes provide valuable insights into the genetic and environmental interactions for the etiology of T2D. Our studies revealed that the emergence of these phenotypes is associated with novel pathophysiological mechanisms, such as low insulin secretion capacity associated with high CD36 expression in pancreatic β-cells and hypoleptinemia preceding obesity due to low leptin secretion capacity in adipocytes. In addition, ON-DP mice fed an atherogenic diet exhibit accelerated atherosclerosis, likely related to blood glucose fluctuations. These findings provide new perspectives on the pathogenesis of T2D and suggest potential prevention and treatment strategies. This review will present the development strategy of the ON mouse strain, representative metabolic phenotypes, and discuss the mechanisms driving these traits, and explore their relevance to human T2D and obesity.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"13-22"},"PeriodicalIF":1.3,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes mellitus and peripheral artery disease.","authors":"Mitsuyoshi Takahara","doi":"10.1007/s13340-024-00785-8","DOIUrl":"10.1007/s13340-024-00785-8","url":null,"abstract":"<p><p>Atherosclerotic peripheral artery disease (PAD), that is, arteriosclerosis obliterans, is pathologically rooted in atherosclerosis, similar to other cardiovascular diseases. In addition to smoking, hypertension, and dyslipidemia, diabetes mellitus is a major risk factor. People with diabetes mellitus have an elevated risk of developing PAD. PAD in turn increases the risk of diabetic foot ulcers and gangrene in the population. Rest pain, nonhealing ulcers, and gangrene associated with chronic ischemia are known as chronic limb-threatening ischemia (CLTI). This article gives an overview of the link between atherosclerotic PAD, particularly CLTI, and diabetes mellitus. First, the clinical impact of CLTI among patients with diabetes mellitus is presented. Second, its clinical features, including prognosis, comorbidity, occurrence, and seasonality, are mentioned. The clinical management of CLTI is also discussed. Diabetes mellitus has notable clinical impact on CLTI and vice versa. CLTI has different clinical features from those of other atherosclerotic cardiovascular diseases. Its clinical profile also differs between individuals with both diabetes mellitus and CLTI and general people with diabetes mellitus. There is considerable room for improvement in CLTI treatment and management. Clinical measures taken before revascularization, including CLTI risk assessment, prompt diagnosis, and expedited referral to vascular specialists, may enhance CLTI outcomes. Further research is warranted to obtain more evidence.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"7-12"},"PeriodicalIF":1.3,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment to the Reviewers.","authors":"","doi":"10.1007/s13340-024-00782-x","DOIUrl":"https://doi.org/10.1007/s13340-024-00782-x","url":null,"abstract":"","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"199-200"},"PeriodicalIF":1.3,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effects of esaxerenone in patients with type 2 diabetes, diabetic kidney disease, and hypertension (JDDM77).","authors":"Daigaku Uchida, Yasunori Sato, Azuma Kanatsuka, Nobuichi Kuribayashi, Susumu Nakamura, Shigetake Ko, Hiroshi Maegawa","doi":"10.1007/s13340-024-00779-6","DOIUrl":"10.1007/s13340-024-00779-6","url":null,"abstract":"<p><strong>Objectives: </strong>This clinical study assessed the three-year, long-term effects of esaxerenone, a non-steroidal aldosterone receptor blocker, on Japanese patients with type 2 diabetes, diabetic kidney disease, and hypertension who were receiving renin-angiotensin system inhibitors.</p><p><strong>Materials and methods: </strong>Data from a computerized diabetic care database were used to retrospectively compare esaxerenone users (Group A) with non-esaxerenone users (Group B). Propensity score weighting was applied to Group B. The study primarily focused on percent changes in the Urine Albumin-Creatinine Ratio (UACR) from baseline and also examined the estimated Glomerular Filtration Rate (eGFR), blood pressure, serum potassium levels, and HbA1c.</p><p><strong>Results: </strong>There were 199 patients in Group A and 199 in Group B, matched 1:1 using propensity scores. UACR and blood pressure were significantly lower in Group A than in Group B. Geometric mean percent changes in UACR from baseline between the two groups were as follows: - 62.7% at 1 year (95% Confidence Interval (CI): - 91.0 to - 34.1%), - 48.9% at 2 years (95% CI: - 79.4 to - 19.3%), and - 63.8% at 3 years (95% CI: - 107.4 to - 20.2%). Additionally, the present study examined the impact of combining esaxerenone with SGLT2 inhibitors and GLP-1 receptor agonists and showed consistent effects on UACR irrespective of these medications. Esaxerenone slightly lowered eGFR with a low risk of hyperkalemia but did not adversely impact glucose metabolism.</p><p><strong>Conclusions: </strong>Esaxerenone exerted antihypertensive and antialbuminuric effects in patients with type 2 diabetes, diabetic kidney disease, and hypertension.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"153-161"},"PeriodicalIF":1.3,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined associations of education and health literacy with preventive dental visits in patients with diabetes: a nationwide cross-sectional study.","authors":"Kyoko Saito, Yuki Kawai, Hirono Ishikawa, Takahiro Tabuchi, Keisuke Kuwahara","doi":"10.1007/s13340-024-00780-z","DOIUrl":"10.1007/s13340-024-00780-z","url":null,"abstract":"<p><strong>Aim: </strong>Oral health is important in patients with diabetes. While health literacy may promote preventive dental visits, the evidence is sparse among them. Additionally, because education is indicated as a determinant of health literacy, none clarified whether health literacy can mitigate educational inequalities in healthcare-seeking behaviors. We examined combined associations of education and health literacy with preventive dental visits in patients with diabetes.</p><p><strong>Methods: </strong>We used cross-sectional data from the Japan COVID-19 and Society Internet Survey (JACSIS) in 2020. We included 1441 patients reporting to have diabetes currently. Educational level was self-reported. Health literacy was measured using the validated scale. Preventive dental visits in the past 12 months were self-reported. We estimated multivariable-adjusted prevalence ratio (PR) for preventive dental visits.</p><p><strong>Results: </strong>54% of the participants had preventive dental visits; 35% had high health literacy. Overall, high health literacy was significantly associated with preventive dental visits. Being more educated and/or having high health literacy were associated with an increased prevalence of preventive dental visits (<i>P</i> for trend < 0.001). Compared with less education and low health literacy group, adjusted PRs (95% confidence intervals) of preventive dental visits were 1.10 (0.93, 1.31) for less education and high health literacy group, 1.14 (1.00, 1.30) for more education and low health literacy group, and 1.29 (1.13, 1.48) for more education and high health literacy group.</p><p><strong>Conclusions: </strong>The present data suggest that health literacy may help promote preventive dental visits and do not deny the possibility that health literacy can mitigate educational inequalities in patients with diabetes.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13340-024-00780-z.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"145-152"},"PeriodicalIF":1.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of CK2 against endoplasmic reticulum stress in pancreatic β cells.","authors":"Tomoko Takai, Shun-Ichiro Asahara, Hiroko Ikushiro, Kenta Kobayashi, Takato Yano, Yoshiaki Kido, Wataru Ogawa","doi":"10.1007/s13340-024-00775-w","DOIUrl":"10.1007/s13340-024-00775-w","url":null,"abstract":"<p><p>Endoplasmic reticulum (ER) stress due to obesity or systemic insulin resistance is an important pathogenic factor that could lead to pancreatic β-cell failure. We have previously reported that CCAAT/enhancer-binding protein β (C/EBPβ) is highly induced by ER stress in pancreatic β cells. Moreover, its accumulation hampers the response of these cells to ER stress by inhibiting the induction of the molecular chaperone 78 kDa glucose-regulated protein (GRP78). We also demonstrated that C/EBPβ is phosphorylated by CK2, which is reportedly associated with the ER stress signal. In the present study, we aimed to clarify the mechanisms underlying the effect of CK2 on pancreatic β cells using a CK2-specific inhibitor, CX4945, and shRNA-mediated knockdown and overexpression of CK2β, the regulatory subunit of CK2. The results indicate that CK2 was activated in MIN6 cells under ER stress and in pancreatic β cells of a diabetic mouse model. Under normal conditions, CK2 interacted with FL-ATF6α in MIN6 cells and regulated the expression of GRP78 and ERAD-associated proteins. Mechanistically, CK2 activation in MIN6 cells upon the overexpression of the CK2β subunit reduced ER stress signals and the accumulation of unfolded proteins via an increase in GRP78 and ERAD-associated protein levels. These results highlight the important role of CK2 in protecting against ER stress-induced apoptosis by regulating GRP78 and ERAD proteins. CK2 contributed to the clearance of unfolded or misfolded proteins in MIN6 cells under both normal and ER stress conditions. Therefore, CK2 activation could be a promising novel approach for preventing type 2 diabetes.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13340-024-00775-w.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"131-144"},"PeriodicalIF":1.3,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiation, reduction, and proliferation of pancreatic β-cells and their regulatory factors.","authors":"Akari Inada","doi":"10.1007/s13340-024-00774-x","DOIUrl":"10.1007/s13340-024-00774-x","url":null,"abstract":"<p><p>The prevalence of diabetes has increased rapidly in recent years, and many types of therapeutic agents have been developed. However, the main purpose of these drugs is to lower blood glucose levels, and they are not fundamental solutions. In contrast, our research has been aimed at stimulating and inducing β-cell proliferation in vivo and replenishing β-cells. We demonstrated that pancreatic ductal cells are a source of β-cells both after birth and during regeneration after partial duct ligation: cell lineage tracing showed that 39% of growing islets and 50% of adult islets during tissue regeneration contained β-cells differentiated from duct cells. We also examined the factors contributing to β-cell depletion. Insulin and cyclin A genes are tightly regulated by transcriptional activators and repressors, and we found that imbalanced and excessive levels of repressors result in a drastic reduction of insulin and β-cell numbers, leading to severe diabetes. Thus, we searched for factors that induce β-cell proliferation in vivo. In our transgenic (Tg) mice, there was a sex difference in the progression of diabetes and sex steroid hormones were shown to contribute to this. Surprisingly, in diabetic male Tg mice, modulation of sex steroid hormones under certain conditions resulted in a marked increase of β-cells. We identified Greb1 as a factor inducing β-cell proliferation in response to a rapid elevation of E2 levels. This series of studies has demonstrated that islet cells exhibit plasticity and indicates that changes of islet cell mass and function are dynamic and recoverable.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"23-29"},"PeriodicalIF":1.3,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycemic variability and quality of life outcomes after changing to hybrid closed-loop system in Japanese individuals with type 1 diabetes using a conventional predictive low-glucose suspended insulin pump system.","authors":"Ayako Fuchigami, Yuki Kojimahara, Fukumi Yoshikawa, Mariko Higa, Takamasa Ichijyo, Kayoko Ikehara, Hiroshi Uchino, Takahisa Hirose","doi":"10.1007/s13340-024-00778-7","DOIUrl":"10.1007/s13340-024-00778-7","url":null,"abstract":"<p><p>The hybrid closed-loop (HCL) system, Medtronic MiniMed^™ 770G, has been available for use by Japanese individuals with type 1 diabetes mellitus since 2021. The aim of this study was to evaluate the effect of its use on glycemic variability and quality of life (QOL) in this population. This multicenter, open-label, prospective observational study included 14 Japanese individuals with type 1 diabetes mellitus treated with MiniMed^™ 640G. Participants who switched to the 770G system were evaluated for time in range (TIR) and other glycemic outcomes at baseline and at 3 and 12 months post-transition. QOL was assessed using the Diabetes Therapy-Related QOL (DTR-QOL) scale. The mean baseline glycated hemoglobin was 7.52 ± 1.05%, and body mass index (BMI) was 21.78 ± 3.07 kg/m². By study completion, individuals used the HCL system approximately 80% of the time in a day. TIR showed improvement, with an increased achievement ratio of TIR > 70% at 12 months. Hypoglycemia occurrence was minimal at 12 months. In addition, all-time sensor glucose measurements decreased after 12 months, and there were no significant changes in BMI or daily insulin dose. DTR-QOL scores did not significantly differ, possibly owing to increased total alarms and sensor calibration times. Transitioning to the Medtronic MiniMed^™ 770G system led to an improved achievement ratio of TIR > 70% and reduced hyperglycemia at 12 months. However, no significant change in QOL was observed, probably because of the increased number of total alarms.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13340-024-00778-7.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"123-130"},"PeriodicalIF":1.3,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depression in pregnant non-diabetic women and women with gestational diabetes in Bangladesh-a comparative study based on multiple logistic regression.","authors":"Kaniz Fatimah","doi":"10.1007/s13340-024-00777-8","DOIUrl":"10.1007/s13340-024-00777-8","url":null,"abstract":"<p><strong>Background: </strong>Depression and gestational diabetes mellitus (GDM) pose significant challenges during pregnancy. Limited literature exists on depression in women with GDM, with most studies focusing on pre-pregnancy diabetes or postpartum depression. This study fills a crucial gap by specifically investigating and comparing antenatal depression among subjects with and without GDM in Bangladesh, utilizing data from the gestational period.</p><p><strong>Methods: </strong>A cross-sectional study with a convenient, purposive sampling technique was undertaken among 111 pregnant women with (66) and without (45) GDM from September 2017 to March 2018 in the BIRDEM-2 GENERAL HOSPITAL, Dhaka. A semi-structured interview schedule was designed with items relevant to socio-demographics, obstetric history, diabetes, and depression.</p><p><strong>Results: </strong>Different degrees of antenatal depression were identified in 61.3% of the subjects (i.e., 27% had mild, 4.5% had moderate, and 29.7% had severe depression, respectively). Out of 45 non-diabetic mothers, 11 (24.4%) had depression whereas out of 66 GDM mothers, 57 (86.4%) have depression. The exploratory analysis revealed that age group, menstruation history, and presence of GDM significantly affected depression but the multiple logistic regression model supported only GDM as a significant factor of depression. All the socio-demographic factors in this study were statistically insignificant to explain depression.</p><p><strong>Conclusion: </strong>The risk of developing depressive symptoms increases with the presence of GDM. Therefore, it is important to screen for depression and provide treatment if necessary in women who are diagnosed with GDM.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"115-122"},"PeriodicalIF":1.3,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High levels of serum dihomo-γ-linolenic acid are associated with non-alcoholic fatty liver disease in type 2 diabetic patients.","authors":"Kohei Mochizuki, Mariko Higa, Kayoko Ikehara, Takamasa Ichijo, Takahisa Hirose","doi":"10.1007/s13340-024-00760-3","DOIUrl":"10.1007/s13340-024-00760-3","url":null,"abstract":"<p><p>An elevated level of saturated fatty acids (SFAs) can cause non-alcoholic fatty liver disease (NAFLD). While n-3 polyunsaturated fatty acids (PUFAs) were shown to improve NAFLD, the effects of n-6 PUFAs in the liver have not been fully elucidated. We examined the association between NAFLD and n-6 PUFAs, particularly dihomo-γ-linolenic acid (DGLA), in patients with type 2 diabetes. A total of 60 patients with type 2 diabetes were included in the study. Patients were categorized into the NAFLD group (<i>n</i> = 35) and non-NAFLD group (<i>n</i> = 25) based on the presence of fatty liver as determined by abdominal ultrasound. We demonstrated that the levels of serum SFAs, specifically palmitic acid and stearic acid, and the levels of n-6 PUFAs, specifically DGLA, and arachidonic acid (AA), were significantly higher in the NAFLD group. The serum palmitic acid, stearic acid, DGLA and AA levels were positively correlated with liver enzyme gamma-glutamyl transpeptidase (GGT). We further demonstrated by multivariate analysis that serum DGLA was a predictor of NAFLD. The serum DGLA level was negatively correlated with blood adiponectin and was positively correlated with blood leptin, high-sensitivity CRP, C-peptide index, and triglyceride-glucose index. Furthermore, delta-5-desaturase (D5D), the AA (product)/DGLA (precursor) ratio calculated from the product-to-precursor ratio of fatty acids, was significantly lower in the NAFLD group. These findings suggest that high serum DGLA levels in NAFLD group may be due to an excessive intake of n-6 PUFAs and changes in desaturase in the human body. High serum DGLA levels may also be associated with insulin resistance and inflammatory factors.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"16 1","pages":"107-114"},"PeriodicalIF":1.3,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}